Virtual Screening

Virtual screening is a computational technique used to identify potential drug candidates from a large library of compounds. It is a cost-effective and efficient way to identify molecules with the desired properties for drug development.

https://ars.els-cdn.com/content/image/1-s2.0-S2213453018301241-fx1_lrg.jpg

There are two main types of virtual screening methods:

1. Structure-based virtual screening: This method uses the 3D structure of a protein target to search for compounds that have a similar shape and electrostatic properties.
2. Ligand-based virtual screening: This method uses the known binding interactions of a known active compound (ligand) with a protein target to search for similar compounds in a library of compounds.

Virtual screening can be used to reduce the number of compounds that need to be tested experimentally, and can also be used in combination with experimental techniques such as high-throughput screening to enhance the overall drug discovery process.

It also can be used in the identification of new inhibitors, to find new target for a specific disease, to predict new interactions between molecules, etc.

Virtual screening is a promising tool in the field of drug discovery, but it is important to note that virtual screening results need to be validated by experimental techniques before moving forward with further development of a compound as a drug candidate.

Structure-based virtual screening example

An example of a structure-based virtual screening method is using the crystal structure of a protein target to search for compounds that have a similar shape and electrostatic properties.

1. First, the 3D structure of the protein target is determined using X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy.
2. Next, a database of small molecules is screened using computational methods such as molecular docking, which simulates the binding of a small molecule to the protein target.
3. The docking calculations generate a score that reflects the binding energy of each molecule with the protein target. The molecules with the highest scores are considered the most likely to bind to the target and are selected as potential hits.
4. The selected molecules can then be further evaluated experimentally using techniques such as binding assays or cellular assays to confirm their binding and activity on the target protein.
5. The compounds that have the highest activity in the experimental assays can then be selected as potential drug candidates for further development.

This example illustrates how virtual screening can be used to identify potential drug candidates from a large library of compounds by using the 3D structure of a protein target to search for compounds that have a similar shape and electrostatic properties.

Ligand-based virtual screening

Ligand-based virtual screening is a computational technique that uses the known binding interactions of a known active compound, or ligand, with a protein target to search for similar compounds in a library of compounds. This method can also be referred as similarity-based virtual screening.

1. First, a known active compound, or ligand, is identified that binds to the protein target of interest.
2. The chemical structure of the ligand is then used to search a database of small molecules for similar compounds. This can be done by comparing the chemical features of the ligand to the compounds in the database using methods such as molecular fingerprints or pharmacophore models.
3. The compounds that are most similar to the ligand are then selected as potential hits and further evaluated.
4. The selected compounds can then be further evaluated experimentally using techniques such as binding assays or cellular assays to confirm their binding and activity on the target protein.
5. The compounds that have the highest activity in the experimental assays can then be selected as potential drug candidates for further development.

Ligand-based virtual screening is an efficient way to identify new compounds that may have similar binding interactions with a target protein as a known active compound. However, it’s important to note that it’s not guaranteed that these compounds will have the same activity or safety profile as the known active compound, and they still need to be evaluated experimentally.